Molnupiravir (taken as an 800mg dose twice daily for five days) does not reduce hospital admissions or deaths in vaccinated adults with COVID-19 infection who are at higher risk of mortality, ...

This article is part of a larger series on the risks of molnupiravir. For a summary of the risks at the level of the individual, see here, and for an overview of the risks on a societal level, see ...

Molnupiravir is the first orally-available antiviral treatment that can be administered directly to people with mild-to-moderate coronavirus disease 2019 (COVID-19). Study: A Randomised -Controlled ...

People with acute COVID-19 who took the antiviral drug molnupiravir (Lagevrio) reported modest improvements in symptoms, less time off from work or study, and less healthcare utilization at 6 months ...

Randomised controlled trial with over 25,000 participants suggests that using the antiviral, molnupiranir, does not decrease deaths or hospital admissions among patients with COVID-19 infection who ...

KENILWORTH, N.J. & MIAMI--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today announced data from six preclinical studies ...

The antiviral drug molnupiravir (Lagevrio) slashed the risk of death from COVID-19 in half when given early to older adults. It also lowered all-cause deaths among older adults in the Czech Republic ...

Credit: Merck. The MOVe-AHEAD study enrolled over 1500 participants 18 years of age and older who resided in the same household with someone who tested positive for SARS-CoV-2. Results were announced ...

KENILWORTH, N.J. & MIAMI--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today announced that a total of approximately 3.1 million ...

When a phase 3 study revealed 30% efficacy for Merck and Ridgeback’s COVID-19 oral antiviral—a significant drop from the 50% figure the company touted at the trial’s interim stage—concerns emerged ...